Abstract
MRI contrast is often enhanced using a contrast agent. Gd3+-complexes are the most widely used metallic MRI agents, and several types of Gd3+-based contrast agents (GBCAs) have been developed. Furthermore, recent advances in MRI technology have, in part, been driven by the development of new GBCAs. However, when designing new functional GBCAs in a small-molecular-weight or nanoparticle form for possible clinical applications, their functions are often compromised by poor pharmacokinetics and possible toxicity. Although great progress must be made in overcoming these limitations and many challenges remain, new functional GBCAs with either small-molecular-weight or nanoparticle forms offer an exciting opportunity for use in precision medicine.
Original language | English |
---|---|
Pages (from-to) | 639-661 |
Number of pages | 23 |
Journal | Future Medicinal Chemistry |
Volume | 10 |
Issue number | 6 |
DOIs | |
State | Published - Mar 2018 |
Keywords
- contrast agent
- gadolinium
- magnetic resonance imaging